Yennurajalingam, Sriram
Basen-Engquist, Karen
Reuben, James M.
Fellman, Bryan M.
Shete, Sanjay
Maddi, Rama
Williams, Janet L.
Dev, Rony
Hui, David
Bruera, Eduardo
Funding for this research was provided by:
Helsinn Therapeutics (002)
Article History
Received: 31 March 2021
Accepted: 22 July 2021
First Online: 31 July 2021
Declarations
:
: The University of Texas MD Anderson Cancer Center Institutional Review Board approved the protocol. Informed consent was obtained from all subjects involved in the study.
: Included as supplementary file.
: The authors declare no conflict of Interest related to study. Funding is as follows: Sriram Yennurajalingam, Helsinn (Research Funding for fatigue study), Bayer (Research Funding for fatigue study), Genentech (Research Funding for Palliative care study); David Hui, Helsinn (Research funding for nausea study), Insys (Research funding for dyspnea study); and Eduardo Bruera (Helsinn: Research Funding for Palliative care study). All other authors declare no conflict of interest.